> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Gilead Reports Promising Veklury Mortality Data
- URL: https://www.fdaweb.com/gilead-reports-promising-veklury-mortality-data/
- Published: 2021-06-21T12:00:00.000Z
- Updated: 2026-09-14T17:04:13.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5149576

Real-world data involving Gilead Sciences’ Veklury (remdesivir) show that the therapy offered a lower mortality risk in hospitalized Covid-19 patients. Data from three retrospective real-world data studies show a reduction in mortality was “observed across a spectrum of baseline oxygen requirements,” the [company says.](https://www.gilead.com/news-and-press/press-room/press-releases/2021/6/gileads-veklury-remdesivir-associated-with-a-reduction-in-mortality-rate-in-hospitalized-patients-with-covid19-across-three-analyses-of-large-ret?ref=fdaweb.com)

For example, one study based on claims data from HealthVerity, performed in collaboration with Aetion, assessed mortality and the likelihood of discharge in hospitalized Covid-19 patients who were treated with Veklury (n=24,856) versus matched controls (n=24,856) between 5/2020 and 5/2021 found that patients receiving Veklury had a statistically significant 23% lower mortality risk compared with controls, Gilead says. Overall, it found a significantly greater likelihood of discharge by Day 28 in patients completing a full five-day Veklury treatment compared with controls.